StreetInsider.com News Articles

VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses

Thu, 08 Jan 2026 10:30:00 -0500

Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with VYLOY plus chemotherapy when data from patients who discontinued early due to common adverse events were censored
Effective management of adverse events remains an important component of supportive care for patients receiving treatment for advanced gastric or GEJ cancer

NORTHBROOK, Ill., Jan. 8, 2026 /PRNewswire/ -- Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses

VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses

Thu, 08 Jan 2026 10:30:00 -0500

Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with VYLOY plus chemotherapy when data from patients who discontinued early due to common adverse events were censored
Effective management of adverse events remains an important component of supportive care for patients receiving treatment for advanced gastric or GEJ cancer

NORTHBROOK, Ill., Jan. 8, 2026 /PRNewswire/ -- Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses

VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses

Thu, 08 Jan 2026 10:30:00 -0500

Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with VYLOY plus chemotherapy when data from patients who discontinued early due to common adverse events were censored
Effective management of adverse events remains an important component of supportive care for patients receiving treatment for advanced gastric or GEJ cancer

NORTHBROOK, Ill., Jan. 8, 2026 /PRNewswire/ -- Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses

VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses

Thu, 08 Jan 2026 10:30:00 -0500

Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with VYLOY plus chemotherapy when data from patients who discontinued early due to common adverse events were censored
Effective management of adverse events remains an important component of supportive care for patients receiving treatment for advanced gastric or GEJ cancer

NORTHBROOK, Ill., Jan. 8, 2026 /PRNewswire/ -- Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses

VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses

Thu, 08 Jan 2026 10:30:00 -0500

Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with VYLOY plus chemotherapy when data from patients who discontinued early due to common adverse events were censored
Effective management of adverse events remains an important component of supportive care for patients receiving treatment for advanced gastric or GEJ cancer

NORTHBROOK, Ill., Jan. 8, 2026 /PRNewswire/ -- Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses

VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses

Thu, 08 Jan 2026 10:30:00 -0500

Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with VYLOY plus chemotherapy when data from patients who discontinued early due to common adverse events were censored
Effective management of adverse events remains an important component of supportive care for patients receiving treatment for advanced gastric or GEJ cancer

NORTHBROOK, Ill., Jan. 8, 2026 /PRNewswire/ -- Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses

VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses

Thu, 08 Jan 2026 10:30:00 -0500

Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with VYLOY plus chemotherapy when data from patients who discontinued early due to common adverse events were censored
Effective management of adverse events remains an important component of supportive care for patients receiving treatment for advanced gastric or GEJ cancer

NORTHBROOK, Ill., Jan. 8, 2026 /PRNewswire/ -- Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses

VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses

Thu, 08 Jan 2026 10:30:00 -0500

Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with VYLOY plus chemotherapy when data from patients who discontinued early due to common adverse events were censored
Effective management of adverse events remains an important component of supportive care for patients receiving treatment for advanced gastric or GEJ cancer

NORTHBROOK, Ill., Jan. 8, 2026 /PRNewswire/ -- Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses

VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses

Thu, 08 Jan 2026 10:30:00 -0500

Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with VYLOY plus chemotherapy when data from patients who discontinued early due to common adverse events were censored
Effective management of adverse events remains an important component of supportive care for patients receiving treatment for advanced gastric or GEJ cancer

NORTHBROOK, Ill., Jan. 8, 2026 /PRNewswire/ -- Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses

VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses

Thu, 08 Jan 2026 10:30:00 -0500

Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with VYLOY plus chemotherapy when data from patients who discontinued early due to common adverse events were censored
Effective management of adverse events remains an important component of supportive care for patients receiving treatment for advanced gastric or GEJ cancer

NORTHBROOK, Ill., Jan. 8, 2026 /PRNewswire/ -- Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses

VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses

Thu, 08 Jan 2026 10:30:00 -0500

Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with VYLOY plus chemotherapy when data from patients who discontinued early due to common adverse events were censored
Effective management of adverse events remains an important component of supportive care for patients receiving treatment for advanced gastric or GEJ cancer

NORTHBROOK, Ill., Jan. 8, 2026 /PRNewswire/ -- Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses

VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses

Thu, 08 Jan 2026 10:30:00 -0500

Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with VYLOY plus chemotherapy when data from patients who discontinued early due to common adverse events were censored
Effective management of adverse events remains an important component of supportive care for patients receiving treatment for advanced gastric or GEJ cancer

NORTHBROOK, Ill., Jan. 8, 2026 /PRNewswire/ -- Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses

VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses

Thu, 08 Jan 2026 10:30:00 -0500

Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with VYLOY plus chemotherapy when data from patients who discontinued early due to common adverse events were censored
Effective management of adverse events remains an important component of supportive care for patients receiving treatment for advanced gastric or GEJ cancer

NORTHBROOK, Ill., Jan. 8, 2026 /PRNewswire/ -- Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses

VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses

Thu, 08 Jan 2026 10:30:00 -0500

Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with VYLOY plus chemotherapy when data from patients who discontinued early due to common adverse events were censored
Effective management of adverse events remains an important component of supportive care for patients receiving treatment for advanced gastric or GEJ cancer

NORTHBROOK, Ill., Jan. 8, 2026 /PRNewswire/ -- Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses

VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses

Thu, 08 Jan 2026 10:30:00 -0500

Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with VYLOY plus chemotherapy when data from patients who discontinued early due to common adverse events were censored
Effective management of adverse events remains an important component of supportive care for patients receiving treatment for advanced gastric or GEJ cancer

NORTHBROOK, Ill., Jan. 8, 2026 /PRNewswire/ -- Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses

VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses

Thu, 08 Jan 2026 10:30:00 -0500

Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with VYLOY plus chemotherapy when data from patients who discontinued early due to common adverse events were censored
Effective management of adverse events remains an important component of supportive care for patients receiving treatment for advanced gastric or GEJ cancer

NORTHBROOK, Ill., Jan. 8, 2026 /PRNewswire/ -- Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses

VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses

Thu, 08 Jan 2026 10:30:00 -0500

Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with VYLOY plus chemotherapy when data from patients who discontinued early due to common adverse events were censored
Effective management of adverse events remains an important component of supportive care for patients receiving treatment for advanced gastric or GEJ cancer

NORTHBROOK, Ill., Jan. 8, 2026 /PRNewswire/ -- Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses

VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses

Thu, 08 Jan 2026 10:30:00 -0500

Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with VYLOY plus chemotherapy when data from patients who discontinued early due to common adverse events were censored
Effective management of adverse events remains an important component of supportive care for patients receiving treatment for advanced gastric or GEJ cancer

NORTHBROOK, Ill., Jan. 8, 2026 /PRNewswire/ -- Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses

VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses

Thu, 08 Jan 2026 10:30:00 -0500

Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with VYLOY plus chemotherapy when data from patients who discontinued early due to common adverse events were censored
Effective management of adverse events remains an important component of supportive care for patients receiving treatment for advanced gastric or GEJ cancer

NORTHBROOK, Ill., Jan. 8, 2026 /PRNewswire/ -- Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses

VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses

Thu, 08 Jan 2026 10:30:00 -0500

Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with VYLOY plus chemotherapy when data from patients who discontinued early due to common adverse events were censored
Effective management of adverse events remains an important component of supportive care for patients receiving treatment for advanced gastric or GEJ cancer

NORTHBROOK, Ill., Jan. 8, 2026 /PRNewswire/ -- Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses

VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses

Thu, 08 Jan 2026 10:30:00 -0500

Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with VYLOY plus chemotherapy when data from patients who discontinued early due to common adverse events were censored
Effective management of adverse events remains an important component of supportive care for patients receiving treatment for advanced gastric or GEJ cancer

NORTHBROOK, Ill., Jan. 8, 2026 /PRNewswire/ -- Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses

VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses

Thu, 08 Jan 2026 10:30:00 -0500

Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with VYLOY plus chemotherapy when data from patients who discontinued early due to common adverse events were censored
Effective management of adverse events remains an important component of supportive care for patients receiving treatment for advanced gastric or GEJ cancer

NORTHBROOK, Ill., Jan. 8, 2026 /PRNewswire/ -- Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses

Astellas to Present at 44th Annual J.P. Morgan Healthcare Conference

Tue, 06 Jan 2026 18:30:00 -0500

TOKYO, Jan. 6, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced it will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026, in San Francisco, Calif. As a global leader in life sciences, Astellas will use this premier platform to highlight its key strategic focuses and the tangible progress achieved to date in support of delivering long-term impact for patients, partners, and shareholders.

Astellas to Present at 44th Annual J.P. Morgan Healthcare Conference

Tue, 06 Jan 2026 18:30:00 -0500

Astellas to Present at 44th Annual J.P. Morgan Healthcare Conference

Tue, 06 Jan 2026 18:30:00 -0500